StockData
Atara Biotherapeutics, Inc. logo

Atara Biotherapeutics, Inc. (ATRA) stock

ATRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$7.70−0.23 (-2.90%)

Close on Nov 13, 2026Market cap $77.29MP/E –Yield –

Atara Biotherapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Atara Biotherapeutics's pe ratio was 1.1× on Apr 30, 2026.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Apr 30, 20261.1×−7.2
2025Dec 31, 20258.3×–

More Atara Biotherapeutics figures

See a number that looks wrong?